非小细胞肺癌中DEC1与cyclinD1的表达及其临床意义

目的：分析differentiated embryonic chondrocyte expressed gene 1（DEC1）和cyclin D1在非小细胞肺癌组织中的表达和相关性及其与临床病理因素间的关系。方法：采用免疫组化方法检测DEC1和cyclin D1在134例非小细胞肺癌中的表达情况。结果：在134例非小细胞肺癌中,DEC1细胞核的平均阳性表达率为（27.6±9.26）%,明显低于DEC1癌旁正常组织中细胞核的平均阳性表达率（84.3±19.70）%。DEC1表达下调或缺失与肺癌的低分化（P=0.008）以及高p-TNM分期（P=0.001）相关。而cyclin D1表达与肺癌低分化（P=0.003）,肿瘤大小（P=0.038）,高p-TNM分期（P=0.017）及淋巴结转移（P=0.037）正相关。并且DEC1在肺癌中的细胞质表达与cyclin D1的表达显著负相关（P=0.003）。结论：DEC1表达与cyclin D1表达负相关,并与肿瘤分化,肺癌患者高p-TNM分期负相关。     

NF-κB、cyclin D1和p27在非细胞肺癌中的表达及意义

目的：探讨核转录因子-KB（NF-κB）、细胞周期素DI（cyclin D1）和p27在非小细胞肺癌中的表达及临床意义。方法：应用免疫组化S-P法检测58例非小细胞肺癌（NSCLC）和15例正常肺组织中NF-κBp65、cyclin D1、p27的表达。结果：NSCLC组织中NF-κBp65和cyclin D1的表达明显高于正常肺组织中的表达（P〈0．01），p27表达则明显低于正常肺组织（P〈0．01）。NF-κBp65表达与NSCLC瘤体大小、淋巴结转移、临床分期密切相关（P〈0．05）cyclin D1表达与瘤体大小、肿瘤分化、淋巴结转移、临床分期密切相关（P〈0．05）；p27表达与瘤体大小、肿瘤分化密切相关（P〈0．05）。NF-κBp65与cyclin D1在NSCLC组织中的表达呈正相关（P〈0．05），cyclin D1与p27的表达呈负相关（P〈0．05），NF-κBp65与p27的表达无相关性（P〉0．05）。结论：NF-κB、cyclin D1、p27与非小细胞肺癌的发生、发展有关，检测三种蛋白的表达可以间接判断NSCLC的生物学行为。     

肺癌组织中Atonal homolog 1与Disabled-2的表达及其临床意义

目的：分析Atonalhomolog1（Atohl）和Disabled-2（Dab2）在肺癌组织中的表达及其与临床病理因素间的关系。方法：采用免疫组化方法检测Atohl和Dab2在100例非小细胞肺癌中的表达情况。结果：在100例非小细胞肺癌中,Atohl的细胞质和细胞核的平均阳性表达率分别为82．70％±19．06％和43．10％±27．16％,明显高于Atohl在癌旁正常组织中的细胞质和细胞核的平均阳性表达率（71．80％±19．14％,18．77％±10．54％）。Atohl在细胞核内的表达与肺癌的低分化（P=0．026）负相关,并且在肺腺癌（P=0．002）和女性患者（P=0．042）中阳性率较高。Dab2在细胞核内的表达与肺癌的原发灶T分期负相关（P=0．025）,并且与肺癌的TNM分期相关（P=0．002）。Atohl在肺癌中的细胞质表达与Dab2的细胞质表达显著相关（P〈0．001）。结论：Atohl在细胞核内的表达与肺癌的低分化负相关,Dab2在细胞核内的表达与肺癌患者TNM分期负相关。Atohl和Dab2在肺癌组织中可能具有协同表达的现象。     

NF-κB、cyclin D1和p27在非小细胞肺癌中的表达及意义

目的:探讨核转录因子-κB(NF-κB)、细胞周期素D1(cyclin D1)和p27在非小细胞肺癌中的表达及临床意义.方法:应用免疫组化S-P法检测58例非小细胞肺癌(NSCLC)和15例正常肺组织中NF-κBp65、cyclin D1、p27的表达.结果:NSCLC组织中NF-κBp65和cyclin D1的表达明显高于正常肺组织中的表达(P＜0.01),p27表达则明显低于正常肺组织(P＜0.01).NF-κBp65表达与NSCLC瘤体大小、淋巴结转移、临床分期密切相关(P＜0.05);cyclin D1表达与瘤体大小、肿瘤分化、淋巴结转移、临床分期密切相关(P＜0.05);p27表达与瘤体大小、肿瘤分化密切相关(P＜0.05).NF-κBp65与cyclin D1在NSCLC组织中的表达呈正相关(P＜0.05),cyclin D1与027的表达呈负相关(P＜0.05),NF-κBp65与p27的表达无相关性(P＞O.05).结论:NF-κB、cyclin D1、p27与非小细胞肺癌的发生、发展有关,检测三种蛋白的表达可以间接判断NSCLC的生物学行为.     

Rsf-1在非小细胞肺癌中的表达及意义

目的:分析Rsf-1在非小细胞肺癌中的表达及与临床病理因素的关系.方法:应用Real-time PCR和免疫组化法检测非小细胞肺癌中Rsf-1的mRNA及蛋白表达情况.结果:有84％(21/25)肺癌组织病例中Rsf-1的mRNA含量明显高于对应的正常肺组织(P＜0.001),肿瘤组织中Rsf-1的mRNA平均值是其癌旁正常肺组织均值的2.37倍.免疫组化结果显示68.4％ (67/98)病例存在Rsf-1蛋白过表达,其过表达与肺癌患者的年龄、性别、肿瘤类型、原发肿瘤分级和淋巴结转移等未发现明显的相关性,而与肺癌的低分化和高p-TNM分期呈正相关(P=0.001;P=0.020).结论:肺癌中存在Rsf-1基因的扩增和蛋白的高表达,并与低分化和高p-TNM分期相关.     

非小细胞肺癌组织PCDH9和cyclin D1表达及其临床意义分析

目的探讨原钙黏附蛋白9（protocadherin 9,PCDH9）和细胞周期蛋白D1（cyclin D1）的表达与非小细胞肺癌（non-small cell lung cancer,NSCLC）生物学行为的相关性及其临床意义。方法收集2007-08-01-2013-05-31武警广东总队医院手术切除的NSCLC组织337例,QRT-PCR及免疫组织化学染色方法分别检测其中临床资料完整的142例肿瘤及癌旁组织中PCDH9及cyclin D1基因和蛋白表达,分析其相关性及临床意义。结果在142例肺癌组织中,PCDH9的表达为0.386±0.008,低于癌旁组织的0.994±0.012,差异有统计学意义,t=5.748,P〈0.001;cyclin D1在癌组织中的表达为7.392±0.079,较癌旁组织的1.004±0.007明显增高,差异有统计学意义,t=13.219,P=0.003。同一患者组织标本中的PCDH9与cyclin D1的表达呈负相关,r=-0.478,P=0.009。PCDH9及cyclin D1蛋白的表达与患者性别、年龄和组织来源无关,P值均〉0.05;而与肿瘤的分期、转移、对化疗药物的敏感性及总生存时间相关,差异有统计学意义,P值均〈0.05;PCDH9高表达患者的中位生存时间较低表达者明显延长,差异有统计学意义,χ^2=68.051,P〈0.001,cyclin D1高表达患者的中位生存时间较低表达者缩短,差异有统计学意义,χ^2=74.436,P〈0.001。结论 PCDH9及cyclin D1表达可能与NSCLC发生发展及转移相关,并可作为评估NSCLC恶性生物学行为及预后的参考指标。     

肺癌组织中Atonal homolog1与Disabled-2的表达及其临床意义

目的:分析Atonal homolog 1(Atoh1)和Disabled-2(Dab2)在肺癌组织中的表达及其与临床病理因素间的关系。方法:采用免疫组化方法检测Atoh1和Dab2在100例非小细胞肺癌中的表达情况。结果:在100例非小细胞肺癌中,Atoh1的细胞质和细胞核的平均阳性表达率分别为82.70%±19.06%和43.10%±27.16%,明显高于Atoh1在癌旁正常组织中的细胞质和细胞核的平均阳性表达率(71.80%±19.14%,18.77%±10.54%)。Atoh1在细胞核内的表达与肺癌的低分化(P=0.026)负相关,并且在肺腺癌(P=0.002)和女性患者(P=0.042)中阳性率较高。Dab2在细胞核内的表达与肺癌的原发灶T分期负相关(P=0.025),并且与肺癌的TNM分期相关(P=0.002)。Atoh1在肺癌中的细胞质表达与Dab2的细胞质表达显著相关(P<0.001)。结论:Atoh1在细胞核内的表达与肺癌的低分化负相关,Dab2在细胞核内的表达与肺癌患者TNM分期负相关。Atoh1和Dab2在肺癌组织中可能具有协同表达的现象。     

miRNA-340和cyclin D1在胃癌组织中的表达及临床意义

目的:探讨胃癌组织中miRNA-340（miR-340）和cyclin D1的表达水平,并分析二者与胃癌患者临床病理参数的关系。方法:选取2019年12月至2020年06月期间我院病理科胃癌手术切除组织及对应癌旁正常胃黏膜组织(距离肿瘤边缘≥5 cm)共60例。采用qRT-PCR检测组织中miR-340的表达水平,采用免疫组化染色检测cyclin D1蛋白表达水平,并分析二者与胃癌患者临床病理参数的关系。结果:胃癌组织中miR-340的表达水平（2.38±0.51）明显低于癌旁正常黏膜组织（2.70±0.54）,差异具有统计学意义（P＜0.05）;胃癌组织中cyclin D1蛋白的表达水平（48.33％）明显高于癌旁正常黏膜组织（16.67％）,差异具有统计学意义（P＜0.05）。胃癌组织中miR-340表达与cyclin D1蛋白表达呈负相关（r=-0.367,P＜0.05）。胃癌组织中miR-340的表达与肿瘤直径、肿瘤的分化程度、浸润深度、临床分期有关（P＜0.05）,cyclin D1蛋白的表达与肿瘤的分化程度、浸润深度、临床分期、神经侵犯及淋巴结转移有关（P＜0.05）。结论:胃癌组织中miR-340和cyclin D1蛋白表达异常,且与不良预后相关,二者联合有望成为胃癌诊疗的潜在生物标志物。     

cyclin D1和kip1在肾细胞癌组织中的表达

目的：采用免疫组化方法检测cyclin D1和kip1在肾细胞癌中的表达,以期获得评估肾细胞癌恶性程度及预后评价的指标.方法：将肾细胞癌肿瘤组织及正常组织用免疫组化方法进行染色,按半定量方法进行结果判定,结合临床资料进行分析.结果：cyclin D1和kip1在肿瘤组织与正常组织中的表达具有显著性差异（P＜0.01）.cyclin D1和kip1在不同性别组、年龄组和直径组肿瘤患者组织中的表达对比不具有显著性差异（P＞0.05）.cyclin D1和kip1在不同病理分级组肿瘤患者组织中的表达具有显著性差异（P＜0.01）.kip1表达与肿瘤分化程度呈正相关（r=0.40）.cyclin D1表达与肿瘤分化程度呈负相关（r=0.45）.结论：cyclin D1和kip1在肿瘤细胞的表达呈现一定规律,可以作为判断肾细胞癌肿瘤细胞分化程度及预后的重要指标,同时也为靶向治疗提供了更多的靶点选择.     

NF-kappa B和AP-1在非小细胞肺癌中的表达

背景与目的核因子kappa B（NF-kappa B）和激活蛋白1（AP-1）在细胞凋亡和增生过程中所起的作用逐渐被人们所认知，在肿瘤的形成过程中也扮演着重要的角色。本研究分析了NF-kappaB、AP-1在非小细胞肺癌中的表达，以明确二者之间的相互关系，并进一步研究二者对周期蛋白cyclin D1和caspase 3在非小细胞肺癌中表达的影响。方法应用Western blot检测NFkappaB、AP-1、cyclin D1和caspase 3在非小细胞肺癌中的蛋白表达，应用RT-PCR检测不同NF-kappaB和AP-1表达的肺癌组织中cyclin D1和cAspase 3的mRNA表达。应用相关分析判断NF-kappa B和AP-1的相关性。结果在45例非小细胞肺癌患者中，NF-kappaB和AP-1在肺癌组织中的表达均高于癌旁肺组织中的表达（0．6047比0．2798，P〈0．01）。在NF-kappaB和AP-1较高表达的肺癌组织中，cyclin D1蛋白表达和mRNA表达均增加（P〈0．01），而caspase 3的蛋白表达和mRNA表达减少（P（0．01）。相关分析显示NFkappaB和AP-1有明显的相关性（r=0．800，P（0．01）。结论NF-kappaB和AP-1作为转录因子可能在非小细胞肺癌的形成和发展中起重要作用。     

The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells

The objective of the current study was to investigate the expression pattern and clinicopathological significance of differentiated embryo–chondrocyte-expressed gene 1 (DEC1) in patients with non-small-cell lung cancer (NSCLC). In 118 archived NSCLC tissues, the positive rate of DEC1 was reduced in human lung cancer samples (36/118, 30.5 %) compared with adjacent normal lung tissues (106/118, 89.8 %), as measured by immunohistochemical staining. Loss of DEC1 was correlated with poor differentiation (p?=?0.005) and high p-TNM stage (p?=?0.002). Consistently, downregulation of DEC1 by siRNA knockdown promoted the growth and colony formation in the A549 lung cancer cell line, and overexpression of DEC1 inhibited the growth and colony formation in the BE1 lung cancer cell line. In addition, a significant negative correlation was found between DEC1 and cyclin D1 (p?=?0.014) in 118 cases of NSCLC. Knockdown of DEC1 resulted in the upregulation of cyclin D1, and overexpression of DEC1 led to the downregulation of cyclin D1. Together with the observation that DEC1 bound directly to the promoter region of cyclin D1 in A549 cells, these results indicate that loss of DEC1 may promote tumor progression in NSCLC through upregulation of cyclin D1, and DEC1 might serve as a novel therapeutic target of NSCLC.     

p53、Cyclin D1及PCNA在非小细胞肺癌的表达

目的 研究非小细胞肺癌（NSCLC）中p53、Cyclin D1蛋白表达及与细胞增殖的关系。方法 应用免疫组织化学技术（SP法）检测74例NSCLC中p53、Cyclin D1蛋白和增殖细胞抗原（PCNA）的表达情况。结果 p53蛋白、CyclinD1蛋白在NSCLC中阳性表达率分别为55．41％和37．84％,均明显高于正常肺组织（P1＝0．0031,P2＝0．0429）。 p53蛋白表达与淋巴结转移有密切关系（P＝0．0222）。p53蛋白、CyclinD1蛋白表达分别与PCNA指数有密切关系（P1＝0．001,P2＝0．0009）。p53蛋白与CyclinD1蛋白表达之间未见明显关系（P＞0．05）。结论 p53蛋白和CyclinD1蛋白近表达参与了NSCLC的发生发展,有促进细胞增殖的作用。p53的诊断和评价NSCLC预后的重要参数。     

The Relationships between cyclin D1 Expression and Prognosis of Non-small Cell Lung Cancer

Background and objective cyclin D1 is a member of the cyclin family, and it has been proven that it plaied an important role in tumorigenesis, invasion and metastasis. We performed a retrospective study on the cyclin D1 expression in non-small cell lung cancer (NSCLC) according to the clinical characteristics. Methods One hundred fifteen postsurgical NSCLC patients were investigated. Immunohistochemistry was used to evaluate the cyclin D1 expression. Results Overall survival was significantly lower in patients with cyclin D1-high expression of tumors than those with cyclin D1 low expression of tumors (χ2=5.132, P=0.023). In early stage patients (stage I, II), the overall survival was significantly lower in patients with cyclin D1-high expression of tumors than those with cyclin D1-low expression of tumors (χ2=6.863, P=0.009). cyclin D1 status (hazard ratio=0.630; P=0.035), differentiation (hazard ratio=0.399; P<0.001), and pTNM (hazard ratio=1.576; P<0.001) to be independent prognostic factors for NSCLC patients. Specifically, the cyclin D1 status (hazard ratio=0.188; P=0.008) was a significant prognostic factor for patients with stage I NSCLCs. Conclusion cyclin D1 expression is an independent prognosis factor for postoperative patient in stage I, II NSCLCs.     

非小细胞肺癌cyclin D1基因表达与预后关系的初步探讨

目的 探讨非小细胞肺癌ｃｙｃｌｉｎ Ｄ１基因表达与预后的关系。方法 采用免疫组化Ｅｎｖｉｓｉｏｎ二步法对４６例非小细胞肺癌手术标本进行ｃｙｃｌｉｎ Ｄ１检测,并结合临床随方资料进行分析。结果 ２５例ｃｌｃｉｎ Ｄ１表达阳性,表达率为５４．３％;其中细胞核阳性表达６例,细胞质阳性表达１９例。临床随访资料显示,在ｃｙｃｌｉｎ Ｄ１基因表达阳性的２５例患者中有１０例术后发生远外转移,而ｃｙｃｌｉｎ Ｄ１     

Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer.

Cyclin D1 is one of the G1 cyclins that control cell cycle progression by allowing G1 to S transition. Overexpression of cyclin D1 has been postulated to play an important role in the development of human cancers. We have investigated the correlation between cyclin D1 overexpression and known clinicopathological factors and also its prognostic implication on resected non-small-cell lung cancer (NSCLC) patients. Formalin-fixed and paraffin-embedded tumour tissues resected from 69 NSCLC patients between stages I and IIIa were immunohistochemically examined to detect altered cyclin D1 expression. Twenty-four cases (34.8%) revealed positive immunoreactivity for cyclin D1. Cyclin D1 overexpression is significantly higher in patients with lymph node metastasis (50.0% vs 14.4%, P = 0.002) and with advanced pathological stages (I, 10%; II, 53.8%; IIIa, 41.7%, P = 0.048; stage I vs II, IIIa, P = 0.006). Twenty-four patients with cyclin D1-positive immunoreactivity revealed a significantly shorter overall survival than the patients with negativity (24.0 +/- 3.9 months vs 50.1 +/- 6.4 months, P = 0.0299). Among 33 patients between stages I and II, nine patients with cyclin D1-positive immunoreactivity had a much shorter overall survival (29.7 +/- 6.1 months vs 74.6 +/- 8.6 months, P = 0.0066). These results suggest that cyclin D1 overexpression is involved in tumorigenesis of NSCLCs from early stage and could be a predictive molecular marker for poor prognosis in resectable NSCLC patients, which may help us to choose proper therapeutic modalities after resection of the tumor.     

Pin1、β-连接素和细胞周期素D1在老年肺癌组织中的表达及临床意义

Objective:To investigate the expressions and correlations of Pin1,β-catenin and cyclin D1 in elderly lung carcinomas.Methods:The expressions of Pin1,β-catenin and cyclin D1 were examined in the specimens of 92 elderly lung carcinomas and 10 normal lung tissues by immunohistochemistry and explored the relationship between the expression levels and clinicopathological factors.Results:(1) The overexpression of Pin1 and cyclin D1 in lung carcinomas was 46 (50%)cases and 60 (65.22%) cases respectively and 56 (60.82%) cases showed positive immunoreactivity for β-catenin in the nuclear and (or) cytoplasmic fraction in tumor tissues,In normal tissue,the expressions of Pin1 and cyclin D1 were negative,the expression of β-catenin was lied in cell membrane.(2) In lung carcinomas the expressions of Pin1,β-catenin and cyclin D1 correlated with tumor differentiation (P＜0.05).The pesitive expression rate and intensity of Pin1 correlated with tumor stage (P=0.032) and lymph node positive disease (P=0.041).The expression of β-catenin correlated with lymph node positive disease (P=0.012).(3) High expression levels of Pin1 correlated with aberrant β-catenin expression (P=0.000) but did not show a correlation with cyclin D1 (P=0.157).Conclusion:In elderly lung carcinomas,the positive expression of Pin1 causes abnormal accumulation of β-catenin and actives its target gene,however,this target gene was not cyclin DI.The detection of Pin1 expression had some clinical significance in estimating prognosis of elderly patient with lung carcinomas.